Get access

Round window membrane permeability to golimumab in guinea pigs: A pilot study

Authors

  • Soha N. Ghossaini MD,

    Corresponding author
    1. Division of Otolaryngology–Head and Neck Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania, U.S.A
    2. Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania, U.S.A
    3. Penn State College of Medicine, Hershey, Pennsylvania, U.S.A.
    • Send correspondence to Soha N. Ghossaini, MD, Division of Otolaryngology–Head and Neck Surgery, Penn State Hershey Medical Center, 500 University Drive, H091, Hershey, PA 17033. E-mail: sghossaini@gmail.com

    Search for more papers by this author
  • Jenny P. Liu MS,

    1. Penn State College of Medicine, Hershey, Pennsylvania, U.S.A.
    Search for more papers by this author
  • Brett Phillips PhD

    1. Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania, U.S.A
    Search for more papers by this author

  • This work was performed in the Division of Otolaryngology–Head and Neck Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania, U.S.A.

  • Golimumab was donated by Janssen Biotech.

  • This study was supported by a generous grant from the department of Surgery at Penn State Hershey Medical Center, Hershey, Pennsylvania, U.S.A.

  • The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis

Autoimmune inner ear disorder is one of a few types of sensorineural hearing loss that is treatable and potentially reversible. Treatment involves oral steroids and methotrexate. Other treatment modalities have been tried with variable success. All such treatments are systemic, with inherent side effects limiting their effectiveness. Recently, tumor necrosis factor (TNF)-α blockers have been suggested as a modality of treatment. The objective of this study was to assess the round window membrane permeability to golimumab, a TNF-α blocker. This study is the first to look at the feasibility of local golimumab delivery into the inner ear, which may allow for targeted immune modulation of autoimmune inner ear disorders without the consequences of systemic treatment.

Study Design

This is a single-blinded, placebo-controlled, pilot study using guinea pigs to assess round window membrane permeability to golimumab.

Methods

Golimumab was instilled into the guinea pigs' middle ear. Inner ear fluid was sampled through the round window membrane after approximately 30 minutes of drug exposure. Golimumab presence in the inner ear was assessed by enzyme-linked immunosorbent assay in both drug-treated and control ears.

Results

Higher concentrations of golimumab were detected in the inner ear fluid samples of golimumab-exposed ears than in the control ears. The difference was statistically significant (P < .001).

Conclusions

Golimumab crosses the round window membrane and is detected in measurable concentrations in the inner ear fluid after 30 minutes of exposure to the membrane. Further studies are needed to learn its pharmacokinetics and the time needed to reach optimal concentration in the inner ear.

Level of Evidence

NA. Laryngoscope, 123:2840–2844, 2013

Ancillary